Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MannKind Breathing Easier After FDA Diabetes Safety Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Trials for inhaled insulin Afresa were already designed to satisfy new cardiovascular risk guidelines, firm says.

You may also be interested in...



NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner

Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.

NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner

Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development

Related Content

Topics

UsernamePublicRestriction

Register

PS067170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel